Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 28 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.23275 | 08:15:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.23275 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 28 | - | 0.1456 - 0.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:00:01 | 28 | $ 0.22 | USD |
CytoDyn Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 214.16M | 921.12M | 556.02M | 0 | -79.82M | -0.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytoDyn (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1649 | 0.2341 | 0.15 | 0.1817736 | 3,962,899 | 0.06785 | 41.15% |
| 1 Month | 0.159 | 0.2341 | 0.15 | 0.1765082 | 1,960,234 | 0.07375 | 46.38% |
| 3 Months | 0.20 | 0.2341 | 0.1456 | 0.174668 | 1,348,260 | 0.03275 | 16.38% |
| 6 Months | 0.26 | 0.3103 | 0.1456 | 0.206261 | 1,486,912 | -0.02725 | -10.48% |
| 1 Year | 0.34 | 0.48 | 0.1456 | 0.2510891 | 1,669,582 | -0.10725 | -31.54% |
| 3 Years | 2.37 | 7.70 | 0.1456 | 1.74 | 2,486,080 | -2.14 | -90.18% |
| 5 Years | 0.5996 | 10.01 | 0.0552 | 2.32 | 2,683,236 | -0.36685 | -61.18% |
CytoDyn (QB) Description
| CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. |
